Skip to content
value.today

Poseida Therapeutics, Inc.

🇺🇸 La Jolla, California, USABiotechnologyFounded 2014
Total raised
$232 M
5 rounds on record
Latest round
$25 M
Aug 2023
First round on record
Dec 2015
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Poseida Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2023$25 MNo. 5$10 to $50 million

Poseida Therapeutics, Inc.: Raise no. 5, Aug 2023

Investors in this round

1 investor had bought by the notice of Aug 11, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Poseida Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brent J. Warner · Executive Officer
  • Harry J. Leonhardt · Executive Officer
  • Johanna M. Mylet · Executive Officer
  • Kristin J. Yarema · Executive Officer
  • Mark J. Gergen · Executive Officer, Director
  • Charles M. Baum · Director
  • Cynthia M. Collins · Director
  • John B. Schmid · Director
  • Luke M. Corning · Director
  • Marcea B. Lloyd · Director
  • Rafael J. Amado · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Johanna Mylet, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 11, 2023. Read the notice at the SEC.

equitySEC
Mar 2019$142 MNo. 4$50 to $250 million

Poseida Therapeutics, Inc.: Raise no. 4, Mar 2019

Investors in this round

17 investors had bought by the notice of Apr 22, 2019: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Poseida Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$142 M of $150 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Ostertag · Executive Officer, Director
  • Mark Gergen · Executive Officer, Director
  • Matthew Spear · Executive Officer
  • Catherine J. Mackey · Director
  • David Hirsch · Director
  • John J. Schmid · Director
  • Marcea Bland Lloyd · Director
  • Noah J. Berkowitz · Director
  • Sean J. Murphy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark J. Gergen, CBO and CFO. Source: SEC Form D, newest notice filed Apr 22, 2019. Read the notice at the SEC.

equitySEC
Mar 2018$31 MNo. 3$10 to $50 million

Poseida Therapeutics, Inc.: Raise no. 3, Mar 2018

Investors in this round

7 investors had bought by the notice of Apr 3, 2018: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Poseida Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Ostertag · Executive Officer, Director
  • Mark Gergen · Executive Officer, Director
  • Adrian Howd · Director
  • David Hirsch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric Ostertag, President and CEO. Source: SEC Form D, newest notice filed Apr 3, 2018. Read the notice at the SEC.

equitySEC
Jul 2017$11 MNo. 2$10 to $50 million

Poseida Therapeutics, Inc.: Raise no. 2, Jul 2017

Investors in this round

16 investors had bought by the notice of Aug 3, 2017: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Poseida Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $15 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Ostertag · Executive Officer, Director
  • Nishan de Silva · Executive Officer, Director
  • Adrian Howd · Director
  • Lars Ekman · Director
  • Robert Lyons · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nishan de Silva, President. Source: SEC Form D, newest notice filed Aug 3, 2017. Read the notice at the SEC.

equitySEC
Dec 2015$23 MNo. 1$10 to $50 million

Poseida Therapeutics, Inc.: Raise no. 1, Dec 2015

Investors in this round

14 investors had bought by the notice of Dec 24, 2015: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Poseida Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $36 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Ostertag · Executive Officer, Director
  • Nishan de Silva · Executive Officer, Director
  • Lars Ekman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Amount Sold includes amounts paid pursuant to conversion of indebtedness.”

Signed by Nishan de Silva, President. Source: SEC Form D, newest notice filed Dec 24, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Poseida Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2023

That is all the official record says: Poseida Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Poseida Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Malin Corp PLCCompanynot statednot statedHeld Series A, A-1, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Malin Life Sciences Holdings LtdCompanynot statednot statedHeld Series A, A-1, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Novartis AGCompanynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Novartis Pharma AGCompanynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Poseida Therapeutics, Inc.
NameRoleNamed in
Brent J. WarnerExecutive officerAug 2023
Harry J. LeonhardtExecutive officerAug 2023
Johanna M. MyletExecutive officerAug 2023
Kristin J. YaremaExecutive officerAug 2023
Mark J. GergenExecutive officerAug 2023
Eric OstertagExecutive officerApr 2019
Mark GergenExecutive officerApr 2019
Matthew SpearExecutive officerApr 2019
Nishan de SilvaExecutive officerAug 2017
Charles M. BaumDirectorAug 2023
Cynthia M. CollinsDirectorAug 2023
John B. SchmidDirectorAug 2023
Luke M. CorningDirectorAug 2023
Marcea B. LloydDirectorAug 2023
Mark J. GergenDirectorAug 2023
Rafael J. AmadoDirectorAug 2023
Catherine J. MackeyDirectorApr 2019
David HirschDirectorApr 2019
Eric OstertagDirectorApr 2019
John J. SchmidDirectorApr 2019
Marcea Bland LloydDirectorApr 2019
Mark GergenDirectorApr 2019
Noah J. BerkowitzDirectorApr 2019
Sean J. MurphyDirectorApr 2019
Adrian HowdDirectorApr 2018
Lars EkmanDirectorAug 2017
Nishan de SilvaDirectorAug 2017
Robert LyonsDirectorAug 2017